{
    "clinical_study": {
        "@rank": "163339", 
        "brief_summary": {
            "textblock": "The objectives of this study are to determine the effects of isoprinosine in patients\n      diagnosed as having unexplained generalized lymphadenopathy. Variables to be examined will\n      include:\n\n      Signs and symptoms:\n\n        -  Lymphadenopathy.\n\n        -  Fever.\n\n        -  Weight loss.\n\n        -  Occurrence of opportunistic infections.\n\n      Cell-mediated immune system parameters:\n\n        -  T-helper cell (OKT4) numbers and proportions.\n\n        -  T-suppressor cell (OKT8) numbers and proportions.\n\n        -  Natural killer (NK) cell activity.\n\n        -  Lymphocyte blastogenic response to phytohemagglutinin (PHA).\n\n        -  Lymphocyte blastogenic response to pokeweed mitogen (PWM).\n\n        -  Immunoglobulin (IgG, IgA, IgM, IgE, IgD) profile.\n\n        -  Circulating immune complexes. Infections characteristically associated with AIDS, such\n           as Candida albicans, Pneumocystis carinii pneumonia, Cytomegalovirus, Herpes simplex,\n           Cryptococcus, Histoplasma, Toxoplasma, Cryptosporidium, Mycobacterium avium-\n           intracellulare, Legionella, and Isospora.\n\n      Safety parameters:\n\n        -  Blood chemistry including serum uric acid (PurposeA-12).\n\n        -  Complete blood count (CBC).\n\n        -  Platelet count."
        }, 
        "brief_title": "A Study of Isoprinosine in Patients With Lymph Node Disease", 
        "condition": [
            "Lymphatic Disease", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Lymphatic Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with a history of gout, uric acid urolithiasis, uric acid nephrolithiasis, renal\n        dysfunction, or gastric ulceration are excluded.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Systemic corticosteroids.\n\n          -  Cytotoxic immunosuppressive agents.\n\n          -  Radiotherapy.\n\n        Critically ill patients or those with CDC-defined AIDS are excluded.\n\n        Prior Medication:\n\n        Excluded within 1 month of study entry:\n\n          -  Immunotherapy.\n\n        Patients with persistent generalized lymphadenopathy (PGL)."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002297", 
            "org_study_id": "008A", 
            "secondary_id": "ISO-103-USA"
        }, 
        "intervention": {
            "intervention_name": "Inosine pranobex", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Inosine Pranobex"
        }, 
        "keyword": [
            "Inosine Pranobex", 
            "AIDS-Related Complex"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Laguna Hills", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92656"
                }, 
                "name": "Newport Pharmaceuticals International Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Multi-Center Double-Blind Placebo-Controlled Study to Investigate the Action of Isoprinosine (Inosiplex) in Patients With Unexplained Generalized Lymphadenopathy", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002297"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Newport Pharmaceuticals International", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 1989"
    }, 
    "geocoordinates": {
        "Newport Pharmaceuticals International Inc": "33.599 -117.699"
    }
}